J Infect Dis. 1994 Apr;169(4):722-9.

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA 3rd, Gupta P, Rasheed S, Coombs R, et al.

Source

Stanford University Medical Center, CA 94305.

Abstract

Drug resistance conferred by specific human immunodeficiency virus type 1 (HIV-1) pol gene mutations has been associated with clinical progression in HIV-infected patients receiving anti-retroviral therapy. This study examined drug susceptibilities and pol mutations of HIV-1 strains from patients treated for 1 year with zidovudine, didanosine (ddI), or zidovudine and ddI. Ten (42%) of 24 patients receiving combination therapy versus 8/26 (31%) receiving only zidovudine had HIV-1 strains with phenotypic zidovudine resistance or a zidovudine resistance pol mutation at codon 215 (P = .6). In contrast, a ddI resistance mutation at codon 74 was less common among patients receiving combination therapy (2/24) than among those receiving ddI only (17/26; P < .001). Two patients receiving combination therapy developed resistance to zidovudine and ddI; they had HIV strains with amino acid mutations at codons 62, 75, 77, 116, and 151. Combination therapy with zidovudine and ddI selects for zidovudine-resistant HIV-1 strains lacking a ddI resistance mutation and for multidrug-resistant strains containing novel pol mutations.

PMID:: 8133086; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

HIV/AIDS Medicines - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. [J Infect Dis. 1995]
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. J Infect Dis. 1995 Jul; 172(1):70-8.
Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. [J Virol. 1995]
Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S. J Virol. 1995 Jun; 69(6):3510-6.
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215. [J Clin Virol. 2000]
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Rusconi S, La Seta Catamancio S, Sheridan F, Parker D. J Clin Virol. 2000 Dec; 19(3):135-42.
Review Studies of zidovudine in combination with didanosine and zalcitabine. [J Acquir Immune Defic Syndr Hu...]
Review Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 1:S52-6.
Review Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. [Am J Med. 1997]
Review Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
Mayers DL. Am J Med. 1997 May 19; 102(5B):70-5.

See reviews... See all...

Cited by 45 PubMed Central articles

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. [HIV Seq Compend. 2001]
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.
Shafer RW, Dupnik K, Winters MA, Eshleman SH. HIV Seq Compend. 2001; 2001:1-51.
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. [Nucleic Acids Res. 2012]
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, et al. Nucleic Acids Res. 2012 Jan; 40(1):345-59. Epub 2011 Sep 8.
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. [PLoS One. 2011]
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.
Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, Sakagami Y, Oka S, Singh K, Sarafianos SG. PLoS One. 2011 Jan 13; 6(1):e16242. Epub 2011 Jan 13.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
MedGen
Related information in MedGen
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Combination therapy with zidovudine and didanosine selects for drug-resistant hu...
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
J Infect Dis. 1994 Apr ;169(4):722-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: